Back to top
more

Kymera Therapeutics (KYMR)

(Delayed Data from NSDQ)

$36.01 USD

36.01
378,756

+1.06 (3.03%)

Updated May 20, 2024 04:00 PM ET

After-Market: $36.21 +0.20 (0.56%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for KYMR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Kymera Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 375 407 442 296 92
Receivables 15 0 0 1 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 15 12 9 6 1
Total Current Assets 405 419 451 302 93
Net Property & Equipment 48 13 12 11 4
Investments & Advances 61 152 125 163 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 8 9 8 2 2
Total Assets 576 603 606 487 117
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 7 4 4 4 3
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 1 1 1 1 1
Accrued Expenses 34 28 23 10 5
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 38 36 62 93 23
Total Current Liabilities 86 71 93 111 35
Mortgages 0 0 0 0 0
Deferred Taxes/Income 17 28 39 78 30
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 1 1 1 1 1
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 181 113 146 203 82
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 109
Common Stock (Par) 0 0 0 0 0
Capital Surplus 926 879 689 413 2
Retained Earnings -531 -384 -229 -129 -76
Other Equity -1 -5 -1 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 395 490 460 284 35
Total Liabilities & Shareholder's Equity 576 603 606 487 117
Total Common Equity 395 490 460 284 -74
Shares Outstanding 55.40 54.80 51.30 44.40 NA
Book Value Per Share 7.13 8.94 8.96 6.39 0.00

Fiscal Year End for Kymera Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 521 375 358 368 397
Receivables 0 15 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 17 15 18 18 15
Total Current Assets 537 405 376 385 412
Net Property & Equipment 49 48 36 27 17
Investments & Advances 224 61 77 105 119
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 8 8 9 9 9
Total Assets 868 576 552 582 614
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 7 7 5 4 6
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 1 1 1 1 1
Accrued Expenses 16 34 26 22 19
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 23 38 28 25 33
Total Current Liabilities 56 86 63 55 62
Mortgages 0 0 0 0 0
Deferred Taxes/Income 24 17 16 20 25
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 1 1 1 1 1
Other Non-Current Liabilities 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 157 181 157 147 152
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,292 926 914 903 890
Retained Earnings -579 -531 -516 -464 -425
Other Equity -2 -1 -2 -4 -3
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 711 395 396 435 462
Total Liabilities & Shareholder's Equity 868 576 552 582 614
Total Common Equity 711 395 396 435 462
Shares Outstanding 61.30 55.40 55.40 55.40 55.30
Book Value Per Share 11.60 7.13 7.14 7.86 8.35